3 Annual Review on Head & Neck Cancers...Uncommon (≥1/1000,

For registration visitwww.yearinreview.in/airhnc

Academic Partners

3rd Annual Review onHead & Neck Cancers

Organized by

• Dr. B. K. Smruti • Dr. Mehul Bhansali• Dr. Kumar Prabhash

Organizing Chairpersons

• Dr. Mandar Deshpande• Dr. Sewanti Limaye• Dr. Kaustav Talapatra• Dr. Vanita Noronha

Organizing Secretaries

Password: hnc123Meeting ID: 895 1730 1984

Daily Quiz for Students

13th, 19th, 20th & 21st June, 2020

WEBINAR ONLIVE Zoom

SCIENTIFIC PROGRAM

4.30 pm - 8.30 pm

https://www.yearinreview.in/airhnc

Academic Partners

Dear Doctor,

On behalf of the organizing committee and Mumbai Oncology Association, we are pleased to invite you to the "3rd Annual Review on Head and Neck Cancers Conference". The will be a virtual conference and will be held through online webinar on 13-19-20-21 June 2020 (4 Hours a day).

This 3rd Annual Review on Head and Neck Cancers Conference 2020 will provide practitioners an update in head and neck cancers with a comprehensive overview of the current standard of care practices as well as review of evolving and innovative treatment approaches.

"The focus of this conference will be on latest in multidisciplinary approach to head and neck treatment, novel treatment breakthroughs and leading research publications and current best practices in supportive and survivorship care."

We will also cover important publications on cutaneous cancers, endocrine malignancies and skull-based cancers. Pertinent reconstructive and rehabilitative issues will similarly be addressed during specific sessions. Open interaction between faculty and participants will be encouraged throughout the sessions with particular emphasis during the scheduled "Tumor Board" sessions and Q & A periods.

This 3rd ARHNC conference have daily quiz for students with attractive prizes.

Looking forward to your participation.

Organized by

Regards,

Organizing ChairpersonsDr. B. K. Smruti Dr. Mehul Bhansali Dr. Kumar Prabhash

Organizing SecretariesDr. Mandar DeshpandeDr. Sewanti LimayeDr. Kaustav TalapatraDr. Vanita Noronha

Academic Partners Organized by

Patrons

• Dr. Deepak Parikh • Dr. Pankaj Chaturvedi • Dr. R. C. Mistry

Scientific Advisory Committee

• Dr. Alok Thakar • Dr. Arnab Gupta • Dr. Ashok D. Dhoble

• Dr. Avinash Pandey

• Dr. Hemant Malhotra • Dr. Monali Swain

• Dr. Poonam Joshi • Dr. Prathmesh Pai • Dr. Randeep Singh

• Dr. Ravindar Singh • Dr. Rohit Pai • Dr. Sandeep Goyle

• Dr. Sarbani Laskar • Dr. Sharad Desai

• Dr. Vikram D. Kekatpure

• Dr. Shivakumar Thiagarajan

• Dr. Vijay Patil • Dr. Yogesh Dabholkar

• Dr. Arun Balaji

• Dr. Neha Mittal

• Dr. Abhishek Mahajan• Dr. Ajay Doiphode

Academic Coordinators

• Dr. Abhishek Vaidya • Dr. Akhil Kapoor • Dr. Amit Kumar

• Dr. Apurva Garg

• Dr. Rakesh Katna • Dr. Shilpi Sharma • Dr. Trinanjan Basu

• Dr. Nikhil Kalyani • Dr. Rohit Malde • Dr. Eapen Thomas

• Dr. Pritanjali Singh• Dr. Mitali Dandekar

Merck

For

the

use

of a

Reg

iste

red

Med

ical

Pra

ctitio

ner

or a

Hos

pita

l or

a L

abor

ator

y O

nly.

IN

D/E

RB/0

320/

0056

EXP

03/2

2SCHEDULE H PRESCRIPTION DRUG – CAUTION Not to be sold by retail without the prescription of a Registered Medical PractitionerWarning: To be sold by retail on the prescription of a Oncologist onlyBefore prescribing ERBITUX, please consult full prescribing information. Presentation: *ERBITUX 5 mg/mL solution for infusion. Excipients: sodium chloride, glycine, polysorbate 80, citric acid monohydrate, sodium hydroxide, water for injections. Indications : Epidermal growth factor receptor-expressing, RAS wild-type metastatic colorectal cancer (mCRC): in combination with irinotecan-based chemotherapy (CT), or in first-line in combination with FOLFOX, or as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan. Squamous cell carcinoma of the head and neck (SCCHN): in combination with radiation therapy (RT) for locally advanced (LA) disease or with platinum-based chemotherapy (pt-CT) for recurrent and/or metastatic (R/M) disease. Dosage and administration: Once a week, intravenously with an infusion pump, gravity drip or a syringe pump; separate infusion line. Initial dose 400 mg/m2 (should be given slowly with max. infusion rate: 5 mg/min; the recommended infusion period is over 120 mins); subsequent weekly doses 250 mg/m2 (Max. infusion rate: 10 mg/min; recommended over 60 mins). Supervision/monitoring by a physician experienced in antineoplastic therapy throughout infusion and for at least one hour afterwards is required. Resuscitation equipment must be ensured. Prior to first infusion: premedication with antihistamines and corticosteroids at least 1 hour prior to administration of ERBITUX; also recommended for all subsequent infusions. Administer CT not earlier than one hour after ERBITUX infusion. mCRC: administer ERBITUX until disease progression. Wild-type RAS tumor status must be verified prior to first infusion by an experienced laboratory using validated test methods. LA SCCHN: start ERBITUX therapy one week before RT and continue throughout treatment. R/M SCCHN: administer ERBITUX in combination with pt-CT and continue until disease progression. Special Populations: Elderly: no dose adjustment required (limited experience in patients ≥75 years). Pediatric patients (<18 years): efficacy not established, no new safety signals. Others: only patients with adequate renal, hepatic and hematological parameters have been investigated. Contraindications: Known severe hypersensitivity reactions (grade 3/4 NCI CTCAE). In combination with oxaliplatin-containing CT if mutated/unknown RAS status. Contraindications for concomitantly used CT or RT must be considered. Special warnings and precautions: Severe infusion-related reactions (IRRs) including anaphylactic reactions: May commonly occur, in some cases with fatal outcome; immediate and permanent discontinuation of ERBITUX therapy; may necessitate emergency treatment. May be anaphylactic or anaphylactoid in nature or represent a cytokine release syndrome. Symptoms may occur during the first infusion and for up to several hours afterwards or with subsequent infusions and may include bronchospasm, urticaria, increase or decrease in blood pressure, loss of consciousness or shock. In rare cases, angina pectoris, myocardial infarction or cardiac arrest have been observed. The risk for anaphylactic reactions is much increased in patients with a history of allergy to red meat or tick bites or positive results of tests for IgE antibodies against Erbitux. Mild/moderate IRRs: decrease infusion rate, also for all subsequent infusions. Closely monitor patients with reduced performance status (PS) and pre-existing cardio-pulmonary disease. Skin reactions: oral tetracyclines and topical 1% hydrocortisone cream with moisturizer may be considered for prophylactic use and medium to high-potency topical corticosteroids or oral tetracyclines for treatment (acc. to clinical practice guidelines). Severe skin reaction (≥grade 3): interrupt treatment, only resume if reaction resolves to grade 2. Second or third occurrence of severe skin reactions: resume at lower dose (200 mg/m2 after second, 150 mg/m2 after third) only if reaction resolves to grade 2. Fourth occurrence or failure to resolve to grade 2 during interruption: permanent discontinuation. Interstitial lung disease: if diagnosed, discontinuation and appropriate treatment. Electrolyte disturbances: determination of serum electrolyte levels recommended prior to and periodically during treatment. Electrolyte repletion (e.g. hypomagnesaemia; hypokalaemia as a consequence of diarrhea; hypocalcemia, particularly in combination with pt-CT) is recommended. Neutropenia and related infectious complications: careful monitoring is recommended particularly in patients experiencing skin lesions, mucositis or diarrhea that may facilitate the occurrence of infections. Severe and sometimes fatal cardiovascular events: increased frequency associated with age ≥ 65 years or PS has been observed. Patient cardiovascular status, PS and concomitant administration of cardiotoxic compounds (e.g. fluoropyrimidines) should be taken into account. Acute or worsening symptoms of keratitis: refer promptly to an ophthalmologist, consider benefit/risk of continuing use. Confirmed ulcerative keratitis: interruption or discontinuation of ERBITUX. Use with caution in patients with history of keratitis, ulcerative keratitis or severe dry eye (e.g. use of contact lenses). CRC patients with mutated/unknown RAS status: ERBITUX should not be used since negative effects on PFS and OS as add-on to FOLFOX4 have been reported in RAS mutated tumors. There is limited experience in combination with RT in mCRC. Fertility, pregnancy and lactation: Only use during pregnancy or in women with inadequate contraception if potential benefits justify potential risks to fetus. Breast-feeding during treatment and 2 months later is not recommended. Effects on male/female fertility have not been evaluated. Undesirable effects: Very common (≥1/10): skin reactions (e.g. acne-like rash and/or pruritus, dry skin, desquamation, hypertrichosis, or nail disorders, single cases of skin necrosis), hypomagnesaemia, mild/moderate IRRs (e.g. fever, chills, dizziness, dyspnea), increased liver enzyme levels and mucositis, in some cases severe. Mucositis may lead to epistaxis. Common (≥1/100, <1/10): headache, conjunctivitis, diarrhea, nausea, vomiting, fatigue, dehydration, hypocalcemia, anorexia, weight loss, severe IRRs. Uncommon (≥1/1000, <1/100): blepharitis, keratitis, deep vein thrombosis, pulmonary embolism or interstitial lung disease. Very rare (<1/10,000): Stevens-Johnson syndrome/toxic epidermal necrolysis. Frequency not known: superinfection of skin lesions with subsequent complications (e.g. cellulitis, erysipelas, staphylococcal scalded skin syndrome, necrotising fasciitis, sepsis), aseptic meningitis. In combination with local RT in SCCHN: typical undesirable effects of RT (e.g. mucositis, radiation dermatitis, dysphagia or leukopenia, mainly as lymphocytopenia). In combination with ERBITUX: slightly higher rates of severe acute radiation dermatitis, mucositis and late RT-related events. Interactions: Fluoropyrimidines: increased frequency of hand-foot syndrome and cardiac ischaemia (e.g. myocardial infarction and congestive heart failure). Capecitabine and oxaliplatin (XELOX): frequency of severe diarrhoea may be increased. pt-CT: increased frequency of severe leukopenia/neutropenia, which may lead to a higher rate of febrile neutropenia, pneumonia and sepsis. Storage: Store in a refrigerator (2ºC – 8ºC) Shelf life: 48 months

Date of Information: June 2019 Based on CCDS of Cetuximab V.16.0 dated 28th June 2018.For further information refer to full prescribing information or write to:

Merck Specialities Pvt Ltd.,

Godrej One, 8th Floor, Pirojsha Nagar, Eastern Express Highway, Vikhroli (East) Mumbai – 400079

Erbitux (Cetuximab) Abbreviated Prescribing Information:

Our mission never stops

Right time

Right patient

Right response

1. Bonner JA et al. N Engl J Med 2006: 354: 567-568, 2. Curran et al. J Clin Oncol 25: 2191-2197, 3. Guigay J, et al. Ann Oncol 2015;26:1941–1947; 4. Bossi P, et al. Ann Oncol 2017;28:2820–2826;5. Tahara M, et al. Ann Oncol 2018;29:1004–1009; 6. Friesland S, et al. ASCO 2018 (Abstract 6032); 7. Vermorken JB, et al. N Engl J Med 2008;359:1116–1127; 8. Mesia R et al. Ann Oncol 2010:; 21:1967-1973

In Locally advanced SCCHN:• Erbitux+RT prolongs survival & maintains quality of life1,2

• Erbitux+RT helps patients to complete the therapy2

• Erbitux+CT provides consistently high mOS and ORR3-7

• Erbitux+CT improves quality of life through symptom control7,8

In 1L RM SCCHN:

16:15 - 16:55 Quiz for maxillo-facial students based on abstracts presented on day 2 Quiz Master: Eapen Thomas, Oral and Maxillofacial Surgeon, Kerala

Academic Coordinators: Nandini Menon, Medical Oncologist, Mumbai Nikhil Kalyani, Radiation Oncologist, Mumbai Mitali Dandekar, Surgical Oncologist, Patna

Chairpersons : Punita Lal, Radiation Oncologist, Lucknow Sanjay Deshmukh, Surgical Oncologist, Pune

Reviewer: Bhooshan Zade, Radiation Oncologist, Pune17:00 - 17:10 Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Author: Sweet Ping Ng Citation: Cancer. 2019 Jun 1;125(11):1823-9

Stem Cell Sparing IMRT for Head and Neck Cancer Patients: A Double-Blind Author: R. Steenbakkers Citation: ASTRO 2019 : Abstract 32

Reviewer: Naveen Munmudi, Radiation Oncologist, Mumbai17:10 - 17:20 Reduction of Radiotherapy Dose to the Elective Neck in Head and Neck Squamous Cell Carcinoma; Update of the Long-Term Tumor Control of a Randomized Clinical Trial Author: S. Deschuymer Citation: ASTRO 2019 : Abstract 31

Acute Toxicity Patterns in Adaptive High Precision Radiotherapy for Head and Neck Cancer - a Randomised Controlled Trial Author: H. Vyas Citation: ASTRO 2019 : Abstract 63

SESSION 6: KEY PUBLICATIONS ON NEW INTERVENTIONS IN HEAD ANDNECK CANCERS

Day 3, Saturday, 20th June

Organized byAcademic Partners

Scientific Program



Scientific Program

Reviewer: Sarath Reddy, Radiation Oncologist, Solapur17:20 - 17:27 Results of a randomized phase III study of dysphagia-optimized intensity modulated radiotherapy (Do-IMRT) versus standard IMRT (S-IMRT) in head and neck cancer. Author: Christopher Nutting Citation: ASCO Abstract 2020

Effect of early integration of specialized palliative care into standard oncologic treatment on the quality of life of patients with advanced head and neck cancers: A phase III randomized controlled trial. ASCO 2020. Poster Highlight-12013 Author: Pankaj Singhai Citation: Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020)

Reviewer: Madhuri Shimpi, Nuclear Medicine, Mumbai17:28 - 17:35 18F-FDG-PET/CT-based treatment planning for definitive (chemo) radiotherapy in patients with head and neck squamous cell carcinoma improves regional control and survival Author: Sven van den Bosch Citation: Radiother Oncol, 2020 Jan;142:107-114

Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685 Author: Val J Lowe Citation: J Clin Oncol 2019 Jul 10;37(20):1704-1712

Reviewer: Abhishek Mahajan, Radiologist, Mumbai17:35 - 17:45 Prognostic role of pre-treatment magnetic resonance imaging (MRI) radiomic analysis in patients with squamous cell carcinoma of the head and neck (SCCHN). Author: Salvatore Alfieri Citation: Journal of Clinical Oncology 38(15_suppl):6553-6553 · May 2020

Multi-Institutional Validation of Deep Learning for Pretreatment Identification of Extranodal Extension in Head and Neck Squamous Cell Carcinoma Author: Benjamin H. Kann Citation: J Clin Oncol 2020 Apr 20;38(12):1304-1311



Scientific Program

Prognostic value of radiological extranodal extension detected by computed tomography for predicting outcomes in head and neck squamous cell cancer patients treated with radical chemoradiotherapy. Author: Abhishek Mahajan Citation: Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 6560-6560

Clinical vs Microscopic Extranodal Extension and Survival in Oropharyngeal Carcinoma in the Human Papillomavirus Era Author: Thomas J Gal Citation: Otolaryngol Head Neck Surg. 2020 May;162(5):693-701

17:45 - 17:50 Take Home Message : Chairpersons

Chairpersons : S Hukku, Radiation Oncologist, Delhi Raj Nagarkar, Surgical Oncologist, Nashik Anil Gupta, Surgical Oncologist, Jaipur

17:50 - 18:20 Panel Discussion on new interventions in head and neck cancers

Moderator: Sarbani Laskar, Radiation Oncologist, Mumbai

Panelists: Vijayanand Reddy, Radiation Oncologist, Hyderabad Ajeet Gandhi, Radiation Oncologist, Delhi Pritanjali Singh, Radiation Oncologist, Patna Deepa Nair, Surgical Oncologist, Mumbai Abhishek Mahajan, Radiologist, Mumbai Rakesh Kumar, Nuclear Medicine, Delhi Mohan H K, Nuclear Medicine, Bangalore


SESSION 7: KEY PUBLICATIONS ON CANCERS OF SALIVARY GLAND



Scientific Program

18:25 - 18:50 Choosing right options to optimize outcomes in 1L RM SCCHN

Moderator: Kumar Prabhash, Medical Oncologist, Mumbai

Panelists: Boman Dhabhar, Medical Oncologist, Mumbai B K Smruti, Medical Oncologist, Mumbai Kaushal Patel, Medical Oncologist, Surat Ashish Kaushal, Medical Oncologist, Ahmedabad Pushpak Chirmade, Medical Oncologist, Mumbai Tushar Patil, Medical Oncologist, Pune

Chairpersons : Harsh Dhar, Surgical Oncologist, Kolkata Mehul Bhansali, Surgical Oncologist, Mumbai

Reviewer: Manoj Mahajan, Medical Oncologist, Udaipur18:50 - 18:55 Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma Author: Vatche Tchekmedyian Citation: J Clin Oncol 2019 Jun 20;37(18):1529-1537

Reviewer: Shilpi Sharma, Surgical Oncologist, Mumbai18:55 - 19:05 Extracapsular Dissection Versus Partial Superficial Parotidectomy for the Treatment of Benign Parotid Tumours Author: Y Q Lin Citation:Int J Oral Maxillofacial Surg 2019

Elective Neck Dissection in Adenoid Cystic Carcinoma of Head and Neck: Yes or No? A Systematic Review Author: Ivika Luksik Citation:Eur Arch Otolaryngol 2019



Scientific Program

Reviewer: Abhishek Bansal, Radiologist, Delhi19:05 - 19:10 The Diagnostic Role of Ultrasonography, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography/Computed Tomography, and Real-Time Elastography in the Differentiation of Benign and Malignant Salivary Gland Tumors: A Meta-Analysis Author: X Kong Citation:Oral Surg Oral Med Oral Pathol Oral Radiol 2019

Reviewer: Chandralekha Tampi, Pathologist, Mumbai19:10 - 19:20 Prognostic markers in salivary gland cancer and their impact on survival Author: Mateusz Szewczyk Citation: Head & Neck. 2019;41:3338–3347

Prognostic Implication of Histopathologic Indicators in Salivary Duct Carcinoma Proposal of a Novel Histologic Risk Stratification Model Author: Masato Nakaguro Citation: Am J Surg Pathol Volume 44, Number 4, April 2020

The Milan System for Reporting Salivary Gland Cytopathology—Proposed modifications to improve clinical utility Author: Francesco Mazzola Citation: Oral Oncol. 2020 Jul;106:104722


Chairpersons : Sanjay Desai, Surgical Oncologist, Indore P K Das, Surgical Oncologist, Cuttack Vicky Khattar, ENT Surgeon, Mumbai

19:25 - 19:50 Panel Discussion on cancers of salivary gland

Moderator: Alok Thakar, Surgical Oncologist, Delhi

Panelists: Gagan Saini, Radiation Oncologist, Delhi Pawan Rane, Surgical Oncologist, Kolhapur Krishnakumar T, Surgical Oncologist, Mumbai Neha Mittal, Pathologist, Mumbai Atul Sharma, Medical Oncologist, Delhi Kanhu Patro, Radiation Oncologist, Delhi Nilesh Sable, Radiologist, Mumbai Vijay Bhaskar, Radiation Oncologist, Bangalore


Chairpersons : S. Kannan, Surgical Oncologist, Chennai Sudeep Sarkar, Surgical Oncologist, Mumbai

Reviewer: Swagnik Chakrabarti, Surgical Oncologist, Varanasi19:55 - 20:05 Comparing the Utility and Surgical Outcomes of Harmonic Focus Ultrasonic Scalpel With Ligasure Small Jaw Bipolar Device in Thyroidectomies: A Prospective Randomized Controlled Trial Author: Shen Han Lee Citation: Ann Surg Onco 2019

Intraoperative nerve monitoring in thyroid surgery—shifting current paradigms Author: Rick Schneider1 Citation: Ann Surg Onco 2019

Reviewer: Arvind Kumar, Medical Oncologist, Patna20:05 - 20:15 Association Between TERT Promoter Mutations and Clinical Behaviors in Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis Author: Jing Yang Citation: Endocrine 2020

Mutation profiles of follicular thyroid tumors by targeted sequencing Author: Huanli Dua Citation: Diagnostic Pathology (2019) 14:39

Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study Author: David L. Steward Citation: JAMAOncol.2019;5(2):204-212

SESSION 8: KEY PUBLICATIONS ON THYROID CANCERS



Scientific Program

Reviewer: Bijal Kulkarni, Pathologist, Mumbai20:15 - 20:25 Systematic Review and Meta-analysis of the Impact of Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features (NIFTP) on Cytological Diagnosis and Thyroid Cancer Prevalence Author: Darin Ruanpeng Citation: Endocrinol Pathol 2019

Utility of Routine Frozen Section of Thyroid Nodules Classified as Follicular Neoplasm Meta-Analysis of Diagnostic Tests Author: Jhorman Grisale Citation: Am J Clin Pathol 2020;153:210-220

Reviewer: Sunil Pasricha, Histopatholoigst, Delhi20:25 - 20:30 A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis Author: Talia L. Fuchs Citation: Am J Surg Pathol . 2020 May 22


Chairpersons : Hetal Marfatia, ENT Surgeon, Mumbai Mohan Jagade, ENT Surgeon, Mumbai

20:35 - 21:00 Panel Discussion on Thyroid Cancers

Moderator: Anil Dcruz, Surgical Oncologist, Mumbai

Panelists: Umanath Nayak, Surgical Oncologist, Hyderabad Dushyant Mandlik, Surgical Oncologist, Mumbai Gouri Pantavaidya, Surgical Oncologist, Mumbai Aparna Gangoli, Patholgist, Bangalore Vamshi Krishna, Medical Oncologist, Hyderabad Prashant Pawar, Surgical Oncologist, Mumbai Ashish Bakshi, Medical Oncologist, Mumbai


21:05 - 21:30 Quiz for Oncology Students based on abstracts of day 3 Quiz master : Amit Kumar, Medical Oncologist, Mumbai



Scientific Program

Zydus Corporate Park’, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, India.Phone : +91-079-71800000, +91-079-48040000 www.zyduscadila.com

Pegfilgrastim 6mg/0.6ml

KitAprepitant Capsules 125 mg / 80 mg

Acute and Delayed Nausea and Vomiting

Fosaprepitant Inj.150 mg / Vial

Filgrastim

Green Gene Technol

ogy

In the prophylaxis & management of Febrile Neutropenia

With comprehensive range of products in supportive care

16:15 - 16:40 Quiz for maxillo-facial students based on abstracts presented on day 3Quiz Master : Eapen Thomas, Oral and Maxillofacial Surgeon, Kerala

Speaker: Ghanashyam Biswas16:40 - 17:00 Indian Experience of Novel Formulation of Docetaxel Academic Coordinators

Pritam Katarai, Medical Oncologist, MumbaiRohit Malde, Radiation Oncologist, MumbaiRakesh Katna, Surgical Oncologist, Mumbai

Chairpersons : K Pavithran, Medical Oncologist, Kochi Govind Babu, Medical Oncologist, Bangalore P K Julka, Radiation Onclogist, Delhi

17:00 - 17:10 Reviewer: Sandeep Goyle, Medical Oncologist, MumbaiAfatinib Versus Methotrexate as Second-Line Treatment in Asian Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Progressing on or After Platinum-Based Therapy (LUX-Head & Neck 3): An Open-Label, Randomised Phase III TrialAuthor: Y. GuoCitation: Ann Oncol. 2019 Nov 1;30(11):1831-1839

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study Author: R. L. FerrisCitation: Ann Oncol. 2020 Apr 12;S0923-7534(20)36434-6

17:10 - 17:15 Reviewer: Ankush Jajodia, Radiologist, DelhiValue of diffusion MR imaging in differentiation of recurrent head and neck malignancies from post treatment changesAuthor: Ankush JajodiaCitation: Oral Oncol. 2019 Sep; 96:89-96


Scientific Program

Day 4, Sunday, 21st June

SESSION 9: KEY PUBLICATIONS IN RECURRENT/METASTATIC HEAD AND NECK CANCERS

17:15 - 17:20 Reviewer: Rakesh Pinninti, Medical Oncologist, HyderabadPembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyAuthor: Barbara BurtnessCitation: Lancet. 2019 Nov 23;394(10212):1915-1928

KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).Author: Kevin Joseph HarringtonCitation: ASCO Abstract 2020

17:20 - 17:30 Reviewer: Vijay Patil, Medical Oncologist, MumbaiPhase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral CancerAuthor: Vijay M. Patil,Citation: J Clin Oncol 2019 Nov 10;37(32):3032-3041

Low-cost oral metronomic versus intravenous chemotherapy in recurrent, inoperable and metastatic head and neck cancer: Phase III Metro-CIS study.Author: Nandini Sharrel MenonCitation: Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 6506-6506

17:30 - 17:40 Reviewer: Ankur Bahl, Medical Oncologist, DelhiPalliative chemotherapy with or without cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Indian tertiary care retrospective analysisAuthor: Ankur Bahl,Citation: Head Neck . 2020 May;42(5):955-962

TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)"Author: Joel GuigayCitation: ASCO Abstract 2020


Scientific Program



Scientific Program


Phase II Trials in Progress CT266 - Safety and efficacy of nimotuzumab in combination with chemotherapy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II studyAuthor: Tao HouCitation: AACR Abstracts CT07.02


Chairpersons : Shekhar Patil, Medical Oncologist, Bangalore V Srinivasan, Radiation Oncologist, Chennai A. K. Anand, Radiation Oncologist, Delhi

17:45 - 18:15 Panel DiscussionModerator: Sewanti Limaye, Medical Oncologist, MumbaiPanelists: Priya Tiwari, Medical Oncologist, Delhi Vanita Norohna, Medical Oncologist, Mumbai Nirmal Rout, Medical Oncologist, Mumbai Venkata Pradeep Babu K, Medical Oncologist, Hyderabad M. V. Chandrakant, Medical Oncologist, Kolkata B Sainath, Medical Oncologist, Hyderabad Amit Ghanekar, Medical Oncologist, Mumbai Shailesh Bondarde, Medical Oncologist, Nashik Maheboob Basade, Medical Oncologist, Mumbai Sumeet Basu, Medical Oncologist, Pune Suman Mallick, Radiation Oncologist, Kolkata

Chairpersons : SVSS Prasad, Medical Oncologist, Hyderabad Vivek Kaushal, Radiation Oncologist, Rohtak

18:20 - 18:25 Reviewer: Nandani Menon, Medical Oncologist, MumbaiPlatinum-based Regimens Versus Cetuximab in Definitive Chemoradiation for Human Papillomavirus-Unrelated Head and Neck CancerAuthor: Thomas H BeckhamCitation: Int J Cancer. 2020 Jul 1;147(1):107-115.

18:25 - 18:30 Reviewer: Rakesh Katna, Surgical Oncologist, MumbaiHead-and-neck paragangliomas: An overview of 54 cases operated at a tertiarycare centerAuthor: Shuchita SinghCitation: South Asian J Cancer. Oct-Dec 2019;8(4):237-240

18:30 - 18:40 Reviewer: Ashay Karpe, Medical Oncologist, MumbaiLong-term outcomes of locally advanced and borderline resectable esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation treated with neoadjuvant chemotherapy.Author: Amit KumarCitation: JCO.2020.38.15_suppl.e18507

DNA methylation-based classification of sinonasal undifferentiated carcinomaAuthor: Snjezana DoganCitation: Modern Pathology (2019) 32:1447–1459

18:40 - 19:00 Panel DiscussionModerator: Adwaita Gore, Medical Oncologist, MumbaiPanelists: Ghanshyam Biswas, Medical Oncologist, Bhubaneswar Sadasivudu Gundeti, Medical Oncologist, Hyderabad Sudhir Nair, Surgical Oncologist, Mumbai Amit Joshi, Medical Oncologist, Mumbai Imran Shaikh, Medical Oncologist, Mumbai Sagar Vaishampayan, Surgical Oncologist, Mumbai


Scientific Program


SESSION 10: KEY PUBLICATIONS IN SPECIAL POPULATION (RARE/HPV/ELDERLY)

19:00 -19:05 Take Home Message : Chairpersons

Chairpersons : Munish Gairola, Radiation Oncologist, Delhi C. S. Mani, Surgical Oncologist, Chennai

19:05 - 19:15 Reviewer: Pooja Nandawani, Radiation Oncologist, Gujarat Long-term Opioid Dependence after Radiation Therapy in Head/Neck CancerPatients: A Retrospective Assessment of Incidence and Risk Factors.Author: L.E.D. SchumacherCitation: ASTRO 2019 : Abstract 1217

A phase III randomized clinical trial of diclofenac versus tramadol forucositis-related pain in head and neck cancer patients undergoing concurrent chemoradiationAuthor: Sachin Babanrao DhumalCitation: JCO.2020.38.15_suppl.e24124

19:15 - 19:20 Reviewer: U S Vishal Rao, Surgical Oncologist, BangaloreOrbital outcomes after orbit-sparing surgery and free flap reconstructionAuthor: Ramez PhilipsCitation: Oral Oncol. 2019 Nov; 98:78-84.

19:20 - 19:25 Reviewer: Geetha Muttath, Radiation Oncologist, KannurLate toxicities among laryngopharyngeal cancers patients treated with different schedules of concurrent chemoradiation at a rural tertiary cancer care centerAuthor: Geetha MuttathCitation: South Asian J Cancer. Oct-Dec 2019;8(4):229-232



Scientific Program


SESSION 11: KEY PUBLICATIONS IN SUPPORTIVE CARE


Scientific Program


Chairpersons : Shekhar Salkar, Surgical Oncologist, Goa B A Krishna, Nuclear Medicine, Mumbai Arnab Gupta, Surgical Oncologist, Kolkata19:30 - 19:45 Reviewer: Vanita Norohna, Medical Oncologist, Mumbai

Biomarkers in head and neck cancers - key publications rapid review

19:45 - 20:15 Status and strategies for the management of head and neck cancer duringCOVID ‐19 pandemic: Indian scenarioModerator: Vikram Kekatpure, Surgical Oncologist, BangalorePanelists: Kumar Prabhash, Medical Oncologist, Mumbai Venkatraman Radhakrishnan, Medical Oncologist, Chennai Pankaj Chaturvedi, Surgical Oncologist, Mumbai Prathamesh Pai, Surgical Oncologist, Mumbai Kaustav Talpatra, Radiation Oncologist, Mumbai Sapna Nangia, Radiation Oncologist, Delhi Sujit Joshi, Pathologist, Pune Abhijit Raut, Radiologist, Mumbai Gauri Panth Vaidya, Surgical Oncologist, Mumbai Venkatesh Rangarajan, Nuclear Medicine, Mumbai Simon Pavamani, Radiation Oncologist, Chennai

20:15 - 20:25 Vote of Thanks

20:30 - 21:00 Quiz for Oncology Students based on abstracts of day 4Quiz master : Akhil Kapoor, Medical Oncologist, TMH, Mumbai

SESSION 12: HEAD AND NECK CANCERS : WHATS NEW & NEW NORMAL


Academic Partners

Dr. Ravindar SinghPresident

Senior Dental Surgeon,Assam

Dr. Sanjay JoshiOMF Surgeon

Hon. Joint Secretary,Mumbai

Dr. Parvesh MehraProfessor & HOD LHMC

Delhi

Dr. Ashok D. DhobleHon.Secretary GeneralSenior Dental Surgeon,

Mumbai


TreasurerProfessor, Head & Neck Surgery,

Mumbai

Dr. Gouri Pantvaidya

Academic Partners

PresidentConsultant Surgeon Head & Neck

Surgical and Professor,New Delhi

Dr. Alok ThakarSecretary

Senior Consultant-Head & NeckSurgical Oncology,

Bangalore

Dr. Vikram D. Kekatpure

Foundation for Head and Neck Oncology (FHNO)

Indian Association of Surgical Oncology (IASO)

Dr. Arnab GuptaPresident

Consultant Surgical Oncologist,Kolkata

Academic Partners

Dr. Rajendra TopraniPresident Elect

Consultant Surgical Oncologist,Delhi

Dr. Sharad DesaiSecretary

Consultant Surgical Oncologist,Sangli

Dr. P. K. DasVice President

Consultant Surgical Oncologist,Cuttack



Indian Society of Medical and Paediatric Oncology (ISMPO)

Academic Partners

Dr. Govind BabuPresident

Consultant Medical Oncologist,Bangalore

Dr. Randeep SinghJoint Secretary

Consultant Medical Oncologist,Delhi

Dr. Kumar PrabhashTreasurer

Consultant Medical Oncologist,Mumbai

Dr. B. K. SmrutiSecretary

Consultant Medical Oncologist,Mumbai


The Association of Otolaryngologists of India (Mumbai Branch)

Academic Partners

Dr. Yogesh DabholkarPresident

Consultant ENT & Head Neck Surgeon,Mumbai

Dr. Ajay DoiphodeHon. Secretary


Dr. Adip ShettyHon. Treasurer


Dr. Ritu ShethVice President


HELP INFLUENCEINNATE IMMUNITY5

Zinc, Selenium,Copper, Vitamins A,C, E,and Folic acid

MICRONUTRIENTS

Helps reducetreatment induced

toxicity &interruptions2,3,4

Helps preventweight loss1

Helps reduceinflammation1

EPA*

CHOOSE EPA*

FORTIFIED NUTRITIONTO HELP TACKLEINFLAMMATION &ITS CONSEQUENCES2 servings of PROSURE® provide~ 2 g of EPA*, 30 g of protein,and 606 kcal of energy

IN-P

RO-P

RM-L

BL-0

002

ASPEN#

RECOMMENDS1

~ 2 g ofEPA*/day

#ASPEN: The American Society for Parenteral andEnteral Nutrition, *EPA: Eicosapentaenoic AcidReferences:1. August DA, et al. JPEN J Parenter Enteral Nutr. 2009;33(5):472–500.2. Trabal J, et al. Nutr Hosp. 2010;25(5):736-740.3. Sánchez-Lara K, et al. Clin Nutr. 2014;33(6):1017–1023.4. Kilic D, et al. Clin Nutr. 2012;7(51):165.5. Erickson KL, et al. J Infect Dis. 2000;182 Suppl 1:S5–S10.*Registered Trademark. Abbott Healthcare Pvt. Ltd., 17th Floor, Godrej BKC, Plot No. C – 68, BKC, Near MCA Club, Bandra (E), Mumbai - 400 051.For the use of Registered Medical Practitioner or a Hospital or a Laboratory only.

3rd Annual Review on Head & Neck Cancers13th, 19th, 20th & 21st June, 2020

Gold Sponsors

Bronze Sponsors

Silver Sponsor

Associate Sponser:

Students Quiz


RIVER ROUTE Creative Group, LLPUnit No. 9, Cama Industrial Premises Co-Op Society Ltd., Sunmil Compound,

Lower Parel (W), Mumbai - 400 013.Mobile: Nilesh Pawar: +91 9975759495/Email: [email protected]

Webinar Managed by

• Daily Quiz for students of all speciality

• Students have to register separately for daily quiz

• Registration of students participating in the quiz will be approved by their respective speciality societies

• Win Attractive Prizes Daily

• For any query related to quiz please write to [email protected]

www.yearinreview.in/airhnc

Find below registration link for the quiz

https://www.yearinreview.in/airhnc

Documents

3 Annual Review on Head & Neck Cancers...Uncommon (≥1/1000,